Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTRONE vs ACTIVELLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (off-label in some contexts),Prostate cancer (palliative therapy, off-label),Breast cancer (palliative therapy in selected cases, off-label)
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation to glucuronides and sulfates. Estrone is interconvertible with estradiol and estriol. Enterohepatic recirculation occurs.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Approximately 96-98% bound to albumin and sex hormone-binding globulin (SHBG)
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
0.8-1.2 L/kg; indicates extensive distribution into tissues, particularly adipose tissue.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Oral: ~5% due to extensive first-pass metabolism; Intramuscular: 100%; Topical: variable, approximately 10% systemically.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of metabolites; monitor estrogenic effects.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In Child-Pugh class A or B, reduce dose by 50% and monitor liver function; start at lowest effective dose.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Not indicated for routine use; individualize for rare conditions (e.g., delayed puberty) under specialist guidance. Typical starting dose: 0.3-0.625 mg orally once daily; adjust based on response and bone age.
Not indicated for use in pediatric patients; safety and efficacy not established.
Start at low end of dosing range (e.g., 0.3-0.625 mg orally once daily); consider increased risk of thromboembolism and endometrial cancer; monitor for adverse effects; use shortest duration possible.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Estrogens increase the risk of endometrial cancer in postmenopausal women. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction, especially in smokers and older women,Malignancy: Increased risk of endometrial cancer (unopposed estrogen) and potential for breast cancer; avoid use in known or suspected estrogen-dependent neoplasia,Dementia: Possible increased risk in women over 65 years,Gallbladder disease: Increased risk of cholelithiasis,Hypertriglyceridemia: May cause severe hypertriglyceridemia with pancreatitis,Hepatic impairment: Use with caution; may be contraindicated in severe disease,Fluid retention: May exacerbate conditions such as asthma, epilepsy, migraine, cardiac or renal dysfunction,Hypocalcemia: Should be used with caution in patients with hypoparathyroidism,Visual abnormalities: Discontinue if sudden vision loss, proptosis, or migraine develops
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except in selected palliative cases),Known or suspected estrogen-dependent neoplasia,Active or history of venous thromboembolism (e.g., DVT, pulmonary embolism),Active arterial thromboembolic disease (e.g., stroke, MI),Severe hepatic impairment or disease,Hypersensitivity to estrone or any component of the formulation
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Grapefruit and grapefruit juice may inhibit estrone metabolism, increasing serum levels and risk of adverse effects. Avoid concomitant high-fat meals as they may alter absorption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tract abnormalities and potential for other adverse effects. Overall: FDA Pregnancy Category X (contraindicated) unless used for specific conditions like progesterone-resistant recurrent pregnancy loss.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Estrone is excreted in human breast milk; M/P ratio not determined. Use during lactation is generally contraindicated as estrogens may suppress milk production and alter milk composition. Alternative agents recommended if breastfeeding.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No recommended dosing in pregnancy due to contraindication; if used, no established dose adjustments exist. Estrogen clearance is increased in pregnancy, but systematic data for estrone are lacking; generally, avoidance is advised.
Not applicable; contraindicated in pregnancy.
Estrone is primarily used in menopausal hormone therapy and has weak estrogenic activity compared to estradiol. Monitor for endometrial hyperplasia in women with an intact uterus; concurrent progestin is required. Assess thromboembolic risk before initiation. Estrone may be less effective for vasomotor symptoms than estradiol. Avoid in patients with breast cancer, liver disease, or undiagnosed vaginal bleeding.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Take estrone exactly as prescribed; do not alter dose or frequency.,Report any unusual vaginal bleeding, breast lumps, or jaundice immediately.,Estrone does not protect against HIV or other sexually transmitted infections.,You may experience nausea, headache, or breast tenderness; contact your doctor if severe.,Do not use estrone if you are pregnant, think you might be pregnant, or are breastfeeding.,Avoid smoking and excessive alcohol consumption to reduce cardiovascular risks.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
"Almasilate, a magnesium-aluminum antacid, can adsorb estrone in the gastrointestinal tract, reducing its absorption and systemic bioavailability. This interaction may lead to subtherapeutic estrone levels, potentially diminishing its therapeutic effects in hormone replacement therapy. Patients may experience inadequate symptom control or hormonal imbalance if the drugs are taken concomitantly without proper timing separation."
"Clarithromycin is a potent CYP3A4 inhibitor and also inhibits P-glycoprotein, significantly decreasing the clearance of estrone, which is metabolized via CYP3A4 and transported by P-gp. This leads to elevated estrone plasma concentrations, increasing estrogenic effects such as thromboembolic risk, breast tenderness, and endometrial proliferation. Clinical vigilance is warranted, especially in patients on hormone replacement therapy or using estrone for menopausal symptoms, as coadministration may precipitate estrogen-related adverse events."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTRONE vs ACTIVELLA, answered by our medical review team.
ESTRONE is a Estrogen that works by Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.. ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTRONE and ACTIVELLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTRONE is: For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.. The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTRONE and ACTIVELLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTRONE is classified as Category C. First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tra. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.